FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136168468> ?p ?o ?g. }

• W3136168468 endingPage "4204" @default.
• W3136168468 startingPage "4195" @default.
• W3136168468 abstract "Neoadjuvant immunotherapy may improve the clinical outcome of regionally advanced operable melanoma and allows for rapid clinical and pathologic assessment of response. We examined neoadjuvant pembrolizumab and high-dose IFNα-2b (HDI) therapy in patients with resectable advanced melanoma.Patients with resectable stage III/IV melanoma were treated with concurrent pembrolizumab 200 mg i.v. every 3 weeks and HDI 20 MU/m2/day i.v., 5 days per week for 4 weeks, then 10 MU/m2/day subcutaneously 3 days per week for 2 weeks. Definitive surgery followed, as did adjuvant combination immunotherapy, completing a year of treatment. Primary endpoint was safety of the combination. Secondary endpoints included overall response rate (ORR), pathologic complete response (pCR), recurrence-free survival (RFS), and overall survival (OS). Blood samples for correlative studies were collected throughout. Tumor tissue was assessed by IHC and flow cytometry at baseline and at surgery.A total of 31 patients were enrolled, and 30 were evaluable. At data cutoff (October 2, 2019), median follow-up for OS was 37.87 months (range, 33.2-43.47). Median OS and RFS were not reached. Radiographic ORR was 73.3% [95% confidence interval (CI): 55.5-85.8], with a 43% (95% CI: 27.3-60.1) pCR rate. None of the patients with a pCR have had a recurrence. HDI and pembrolizumab were discontinued in 73% and 43% of patients, respectively. Correlative analyses suggested that intratumoral PD-1/PD-L1 interaction and HLA-DR expression are associated with pCR (P = 0.002 and P = 0.008, respectively).Neoadjuvant concurrent HDI and pembrolizumab demonstrated promising clinical activity despite high rates of treatment discontinuation. pCR is a prognostic indicator.See related commentary by Menzies et al., p. 4133." @default.
• W3136168468 created "2021-03-29" @default.
• W3136168468 creator A5006107043 @default.
• W3136168468 creator A5006138563 @default.
• W3136168468 creator A5006434494 @default.
• W3136168468 creator A5007239425 @default.
• W3136168468 creator A5011411480 @default.
• W3136168468 creator A5013312057 @default.
• W3136168468 creator A5018176156 @default.
• W3136168468 creator A5020955148 @default.
• W3136168468 creator A5021106659 @default.
• W3136168468 creator A5022244759 @default.
• W3136168468 creator A5023534974 @default.
• W3136168468 creator A5025286759 @default.
• W3136168468 creator A5026029856 @default.
• W3136168468 creator A5026472527 @default.
• W3136168468 creator A5029079928 @default.
• W3136168468 creator A5030169825 @default.
• W3136168468 creator A5032479254 @default.
• W3136168468 creator A5033580931 @default.
• W3136168468 creator A5044474059 @default.
• W3136168468 creator A5049243227 @default.
• W3136168468 creator A5050352682 @default.
• W3136168468 creator A5059127209 @default.
• W3136168468 creator A5059251810 @default.
• W3136168468 creator A5065274525 @default.
• W3136168468 creator A5069042696 @default.
• W3136168468 creator A5081411983 @default.
• W3136168468 creator A5089221394 @default.
• W3136168468 creator A5089516753 @default.
• W3136168468 creator A5089897629 @default.
• W3136168468 creator A5091352114 @default.
• W3136168468 date "2021-03-22" @default.
• W3136168468 modified "2023-10-17" @default.
• W3136168468 title "Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma" @default.
• W3136168468 cites W1555327274 @default.
• W3136168468 cites W1608778557 @default.
• W3136168468 cites W1611944043 @default.
• W3136168468 cites W1854203388 @default.
• W3136168468 cites W2017153151 @default.
• W3136168468 cites W2055901890 @default.
• W3136168468 cites W2063264144 @default.
• W3136168468 cites W2112410464 @default.
• W3136168468 cites W2134007339 @default.
• W3136168468 cites W2143523733 @default.
• W3136168468 cites W2547133566 @default.
• W3136168468 cites W2752210999 @default.
• W3136168468 cites W2752227448 @default.
• W3136168468 cites W2775087755 @default.
• W3136168468 cites W2783914781 @default.
• W3136168468 cites W2883806089 @default.
• W3136168468 cites W2891790933 @default.
• W3136168468 cites W2894584497 @default.
• W3136168468 cites W2894796660 @default.
• W3136168468 cites W2896787895 @default.
• W3136168468 cites W2898179628 @default.
• W3136168468 cites W2900900207 @default.
• W3136168468 cites W2907588392 @default.
• W3136168468 cites W2916647762 @default.
• W3136168468 cites W2919605631 @default.
• W3136168468 cites W2943492451 @default.
• W3136168468 cites W2944319990 @default.
• W3136168468 cites W2947338182 @default.
• W3136168468 cites W2947765148 @default.
• W3136168468 cites W2947828919 @default.
• W3136168468 cites W2955181150 @default.
• W3136168468 cites W2964800251 @default.
• W3136168468 cites W2980554777 @default.
• W3136168468 cites W2991047437 @default.
• W3136168468 cites W2997351648 @default.
• W3136168468 cites W3005037466 @default.
• W3136168468 cites W3019896857 @default.
• W3136168468 cites W3087319279 @default.
• W3136168468 cites W3087401339 @default.
• W3136168468 cites W3087697977 @default.
• W3136168468 cites W3120569005 @default.
• W3136168468 cites W3127822472 @default.
• W3136168468 doi "https://doi.org/10.1158/1078-0432.ccr-20-4301" @default.
• W3136168468 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8338751" @default.
• W3136168468 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33753453" @default.
• W3136168468 hasPublicationYear "2021" @default.
• W3136168468 type Work @default.
• W3136168468 sameAs 3136168468 @default.
• W3136168468 citedByCount "12" @default.
• W3136168468 countsByYear W31361684682021 @default.
• W3136168468 countsByYear W31361684682022 @default.
• W3136168468 countsByYear W31361684682023 @default.
• W3136168468 crossrefType "journal-article" @default.
• W3136168468 hasAuthorship W3136168468A5006107043 @default.
• W3136168468 hasAuthorship W3136168468A5006138563 @default.
• W3136168468 hasAuthorship W3136168468A5006434494 @default.
• W3136168468 hasAuthorship W3136168468A5007239425 @default.
• W3136168468 hasAuthorship W3136168468A5011411480 @default.
• W3136168468 hasAuthorship W3136168468A5013312057 @default.
• W3136168468 hasAuthorship W3136168468A5018176156 @default.
• W3136168468 hasAuthorship W3136168468A5020955148 @default.
• W3136168468 hasAuthorship W3136168468A5021106659 @default.
• W3136168468 hasAuthorship W3136168468A5022244759 @default.

• next